GO:0019894 kinesin binding: Mechanism and Genes

GO:0019894 kinesin binding is a molecular function term describing the selective, non-covalent and stoichiometric interaction of a protein with kinesin, a member of the microtubule-based motor protein superfamily that performs force-generating tasks such as organelle transport and chromosome segregation. Kinesins convert chemical energy from ATP into mechanical work along microtubules, and their activity depends critically on which proteins they bind and how those interactions are regulated. Because kinesin binding determines where, when and how strongly a motor engages its track or its cargo, it sits at the center of intracellular transport, spindle assembly and chromosome movement. Mechanistically, kinesin binding is governed by the nucleotide state of the motor and by the geometry of the interaction with tubulin. Kinesin-microtubule binding depends on both the nucleotide state and the loading direction, meaning that the same motor domain can form a stable or a weak interaction depending on whether it is pulled forward or backward. In addition, the C-terminal tails of tubulin modulate kinesin binding, providing a structural mechanism by which the microtubule itself tunes motor recruitment. These findings explain why kinesin binding is best understood as a dynamic, regulated interface rather than a static lock-and-key event. For researchers, GO:0019894 is important because it connects motor biochemistry to cell biology and disease. Dedicated inhibitors such as kinesin-binding protein (KBP) can switch kinesin into an autoinhibited state, cargo adaptors such as kinectin couple kinesin to organelles and control their motility, and chromokinesins use kinesin binding at chromosomes to support segregation and spindle function. Pharmacological disruption of kinesin binding, for example through an allosteric propofol-binding site, impairs processive movement and offers a route to chemical modulation of motor activity. Together these studies make kinesin binding a tractable target for genetic, biochemical and imaging-based interrogation.

In our own words, GO:0019894 kinesin binding is the molecular function of interacting selectively, non-covalently and stoichiometrically with kinesin, a member of the microtubule-based motor protein superfamily that performs force-generating tasks such as organelle transport and chromosome segregation. The term captures a protein-protein interface: the binding partner recognizes a kinesin motor and forms a defined complex, without covalent modification and without enzymatic turnover of the kinesin itself. Because the interaction is stoichiometric, it is saturable and can be described by binding affinity and complex composition. The definition also implies functional consequence, since kinesins use this binding to carry out force-generating tasks including organelle transport and chromosome segregation.

Kinesin binding matters because it determines whether a microtubule motor is active, inhibited, cargo-coupled or chromosome-associated, and therefore controls processes as diverse as organelle transport, spindle organization and chromosome segregation. The interaction is not constitutive: it is tuned by nucleotide state, loading direction and tubulin C-terminal tails, which makes it a highly regulatable node in the cell. Because dedicated inhibitors such as KBP can lock kinesin in an autoinhibited state, and because small molecules such as propofol can bind kinesin allosterically and disrupt processive movement, kinesin binding is both a fundamental cell-biology problem and a potential therapeutic interface.

The following genes and proteins are experimentally implicated in kinesin binding (GO:0019894) or in the motor complexes through which this function is realized.

Kinesin binding is regulated at several levels. First, the nucleotide state of the motor and the direction of load determine whether a stable interaction forms, so the binding interface is mechanochemically gated. Second, the C-terminal tails of tubulin modulate kinesin binding, meaning that microtubule composition and post-translational state can tune motor recruitment. Third, dedicated inhibitors such as kinesin-binding protein (KBP) can lock kinesin in an autoinhibited state, providing a direct negative regulatory mechanism. Fourth, allosteric sites outside the canonical motor interface, such as the propofol-binding site, can disrupt processive movement, showing that kinesin binding is susceptible to pharmacological regulation. Finally, kinesin-binding-triggered conformation switching of microtubules contributes to polarized transport, indicating that binding can feed back onto the track to influence directional movement.

Chromokinesins use kinesin binding at chromosomes to support chromosome segregation and spindle organization, so perturbations of these interactions can lead to segregation errors and aneuploidy. Because mitotic kinesins are essential for faithful chromosome movement, kinesin-binding interfaces are relevant to cancer cell proliferation and to the biology of genome instability. Experimental models that disrupt chromokinesin binding can therefore be used to test whether a specific interface is required for mitotic fidelity.

Kinectin-kinesin binding domains directly affect organelle motility, so disruption of this adaptor-motor interaction is expected to impair organelle distribution. Such defects are relevant to cell biological phenotypes in which organelle positioning is altered, and they provide a measurable readout for kinesin binding function. Because kinesin binding is cargo-specific, different adaptors can produce distinct organelle phenotypes.

Kinesin-binding protein (KBP) inhibits kinesin by locking it in an autoinhibited state, showing that excessive or inappropriate kinesin binding can suppress motor activity. Conversely, an allosteric propofol-binding site in kinesin disrupts processive movement, demonstrating that pharmacological modulation of kinesin binding can alter motor function. These findings support the idea that kinesin-binding interfaces are druggable and that disease-relevant motor dysfunction may be modulated chemically.

Kinesin-binding-triggered conformation switching of microtubules contributes to polarized transport, linking kinesin binding to the spatial organization of cells. When this mechanism is perturbed, directional transport and cellular polarity can be affected. This makes kinesin binding relevant to developmental and cell-biological contexts in which polarized trafficking is essential.

Recombinant kinesin motor domains and candidate binding partners can be used in co-sedimentation, pull-down or surface-binding assays to measure stoichiometric, non-covalent interaction. Because kinesin-microtubule binding depends on nucleotide state and loading direction, these assays must control nucleotide conditions and, where possible, apply directional load. Tubulin C-terminal tails can be removed or modified to test their contribution to binding.

Single-molecule imaging of kinesin moving on microtubules measures processive movement and can reveal whether a binding partner or compound disrupts motor stepping. Such assays are particularly useful for testing allosteric modulators that bind outside the canonical motor interface. They also allow direct comparison of binding-competent and binding-deficient motor variants.

Fluorescence imaging of organelles or chromosomes in cells expressing tagged kinesin or tagged adaptors can report on kinesin binding in a physiological context. Organelle motility assays are especially informative for kinectin-kinesin interactions, while chromosome-associated signals report on chromokinesin binding. Live imaging can capture the dynamics of binding and release.

CRISPR knockout of a candidate binding partner, followed by rescue with wild-type or binding-deficient constructs, tests whether the interaction is required for the phenotype. Point mutations in the motor or in tubulin can be used to dissect the contribution of specific residues to kinesin binding. Overexpression of an inhibitor such as KBP can test the consequences of excessive binding.

Researchers studying kinesin binding-related genes often need to determine whether a candidate gene is causally involved in motor recruitment, cargo coupling or chromosome movement, and CRISPR-based models provide a direct route to that answer. By combining knockout, point-mutation, knock-in and overexpression strategies with binding and imaging readouts, it becomes possible to move from correlation to mechanism for GO:0019894.

GO:0019894 kinesin binding is a molecular function that captures the selective, non-covalent and stoichiometric interaction of proteins with kinesin motors, the microtubule-based engines responsible for organelle transport and chromosome segregation. The interaction is dynamically regulated by nucleotide state, loading direction and tubulin C-terminal tails, and it can be inhibitory, as in the case of KBP, or cargo-coupling, as in the case of kinectin. Because kinesin binding also contributes to chromosome segregation and polarized transport, and because it can be modulated allosterically, it is a central node for both cell biology and therapeutic exploration. For researchers, the practical path forward is to combine precise genetic models with quantitative binding and imaging assays. CRISPR knockout, point-mutation, knock-in and overexpression strategies allow causal testing of candidate kinesin-binding interfaces, while in vitro and single-molecule assays provide the mechanistic detail. This integrated approach is well suited to clarifying how kinesin binding shapes transport, division and disease-relevant phenotypes.